Company Overview

Johnson & Johnson is a prominent American multinational pharmaceutical, biotechnology, and medical technologies corporation. Headquartered in New Brunswick, New Jersey, its common stock is publicly traded on the New York Stock Exchange (NYSE) and is a component of the Dow Jones Industrial Average. The company was founded in 1886 and consistently ranks among the largest United States corporations, notably at No. 42 on the 2024 Fortune 500 list and 45th on the 2024 Forbes Global 2000. As of 2024, Johnson & Johnson employs approximately 138,000 individuals worldwide, led by Chairman and Chief Executive Officer, Joaquin Duato.

Market Capitalization

As of September 2025, Johnson & Johnson's market capitalization stands at $419.55 Billion USD, positioning it as the 22nd most valuable company globally according to available data.

Business Segments

Johnson & Johnson operates its business through two primary segments: Innovative Medicine and MedTech. In 2023, the company strategically split off its consumer healthcare business into a new publicly traded entity, Kenvue.

Johnson & Johnson Innovative Medicine

This segment is at the forefront of advancing medical treatments. It focuses on developing breakthrough pharmaceutical products for a range of therapeutic areas, including immunology, cardiovascular disease, pulmonary hypertension, infectious diseases, and oncology. Key healthcare areas addressed by Innovative Medicine include Oncology, Immunology, Neuroscience, and Cardiopulmonary conditions. The segment, which incorporates the former Janssen pharmaceutical division, is dedicated to creating potential medicines for complex diseases. Notable products include Xarelto (rivaroxaban) for antithrombotic therapy.

Johnson & Johnson MedTech

Johnson & Johnson MedTech leads innovation at the intersection of biology and technology, aiming to provide treatments with pinpoint precision in challenging anatomical areas. Its portfolio focuses on restoring anatomy and reimagining healing through smarter, less invasive, and more personalized treatments. The segment addresses complex health challenges in areas such as Cardiovascular health, Orthopaedics, Surgery, and Vision. It encompasses businesses like Abiomed and Biosense Webster electrophysiology.

Financial Performance

Full Year 2024 Results

- Q4 2024: Reported sales grew by 5.3% to $22.5 Billion USD, with operational growth of 6.7% and adjusted operational growth of 5.7%. Earnings per share (EPS) were $1.41, with Adjusted EPS at $2.04 (both including $(0.22) from acquired IPR&D charges related to the V-Wave acquisition).

- Full Year 2024: Reported sales increased by 4.3% to $88.8 Billion USD, with operational growth of 5.9% and adjusted operational growth of 5.4%. Full-Year EPS was $5.79, and Adjusted EPS was $9.98 (both including $(0.67) from acquired IPR&D charges).

- Annual Revenue & Earnings (2024): Revenue reached $88.82 billion, a 4.30% increase from the previous year's $85.16 billion. Earnings were $14.07 billion, reflecting a decrease of -59.99% year-over-year.

Key Growth Drivers

Johnson & Johnson has demonstrated strong performance across its segments.

- Innovative Medicine: Key products driving growth in Q1 2024 include DARZALEX, ERLEADA, CARVYKTI, and other oncology treatments. The segment is on track for its 13th consecutive year of above-market growth.

- MedTech: Growth is notably propelled by electrophysiology products and other innovative medical devices.

Strategic Investments and Acquisitions

Johnson & Johnson has actively pursued strategic acquisitions to enhance its growth trajectory:

- Shockwave Medical Acquisition (April 2024): Announced for $13.1 billion, this acquisition of a provider of intravascular lithotripsy technology strengthens J&J MedTech's cardiovascular portfolio. The deal was completed by the end of May.

- V-Wave Acquisition (August 2024): A planned acquisition worth up to $1.7 billion to integrate V-Wave's cardiovascular implant technology (Ventura Interatrial Shunt) for heart failure patients into the medical device segment.

- Intra-Cellular Therapies Acquisition (January 2025): Announced acquisition for $14.6 billion of a neurological drug maker specializing in medications for behavioral disorders like schizophrenia, depression, and bipolar disorder.

Over the past year, J&J has committed over $3 billion to external growth opportunities, including acquisitions, licensing deals, and partnerships.

Innovation Pipeline and Future Outlook

Johnson & Johnson maintains a robust pipeline across both its business segments. The company is focusing on areas of high innovation and growth.

- Pipeline Projection: Expected to deliver over 20 novel therapies and more than 50 product expansions by 2030.

- Innovative Medicine Pipeline (by 2030):

- More than 10 assets with the potential to deliver over $5 billion in peak year sales (PYS). This includes five assets highlighted during the 2021 Pharmaceutical Business Review, as well as TALVEY, TECVAYLI, and JNJ-2113.

- Projected Growth Rate: The company projects a compound annual growth rate (CAGR) between 5-7 percent from 2025 to 2030.

Stock Performance

Johnson & Johnson stock (NYSE: JNJ) delivered a remarkable 24% return in 2025, outperforming the S&P 500 healthcare index, which declined by 0.2%. This strong performance reflects investor confidence in the company's strategic transformation and solid growth prospects.

Johnson & Johnson stands as one of the largest and most diversified healthcare companies globally, possessing strong positions in both pharmaceuticals and medical technology. Its ongoing commitment to innovation, strategic acquisitions, and a powerful pipeline positions the company for sustained growth within the evolving healthcare landscape.